Metformin inhibits NF-κB p65/RelA–NLRP3 inflammasome–IL-1β axis, attenuates lipid droplet accumulation, and reprograms CD14/CD16 expression in monocytes exposed to colorectal tumor-conditioned medium
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115299 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Nihel Chahinez Djebri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Molecular Biology and Immunology, W0414100, University of Tlemcen, 13000 Tlemcen, Algeria. Hauptthemen laut MEDLINE: Metformin, Monocytes, Colorectal Neoplasms, Lipid Droplets. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 166 Literaturangaben. Gefördert von: Directorate General for Scientific Research and Technological Development.
Abstract (Originalsprache)
BACKGROUND: Colorectal cancer (CRC) generates a complex tumor microenvironment (TME) known to profoundly alter the function and phenotype of immune cells, including monocytes. Key aspects of this environment can be mimicked by tumor-conditioned medium (TCM). Metformin has emerged as a promising candidate to counteract TCM-induced immune and inflammatory dysregulation. Therefore, this study aimed to evaluate the effects of metformin on NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome expression, monocyte subset distribution, and lipid droplet (LD) accumulation upon exposure to colorectal TCM. METHODS: Assays were performed on primary human monocytes exposed to colorectal TCM in the presence or absence of metformin. RESULTS: TCM significantly increased nitric oxide (NO, p 0.05). CONCLUSIONS: Our findings highlight metformin's selective immunometabolic reprogramming capacity in monocytes exposed to colorectal tumor-derived signals, supporting its potential as a context-specific immunomodulator. This study lays the groundwork for future translational research on metformin as an adjunctive agent in inflammation-driven tumor settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Applied Molecular Biology and Immunology, W0414100, University of Tlemcen, 13000 Tlemcen, Algeria.
- Laboratory of Applied Molecular Biology and Immunology, W0414100, University of Tlemcen, 13000 Tlemcen, Algeria; Surgery Department B of Tlemcen University Hospital Center, 13000 Tlemcen, Algeria.
- Laboratory of Applied Molecular Biology and Immunology, W0414100, University of Tlemcen, 13000 Tlemcen, Algeria. Electronic address: mourad.aribi@univ-tlemcen.dz.
Förderung
- Directorate General for Scientific Research and Technological Development
Zitieren
APA
Djebri, N. C., Zoudji, S., Messaoud, A., Messali, R., Loudjedi, S., & Aribi, M. (2025). Metformin inhibits NF-κB p65/RelA–NLRP3 inflammasome–IL-1β axis, attenuates lipid droplet accumulation, and reprograms CD14/CD16 expression in monocytes exposed to colorectal tumor-conditioned medium. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115299
Vancouver
Djebri NC, Zoudji S, Messaoud A, Messali R, Loudjedi S, Aribi M. Metformin inhibits NF-κB p65/RelA–NLRP3 inflammasome–IL-1β axis, attenuates lipid droplet accumulation, and reprograms CD14/CD16 expression in monocytes exposed to colorectal tumor-conditioned medium. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115299
BibTeX
@article{Djebri2025,
author = {Djebri, Nihel Chahinez and Zoudji, Souad and Messaoud, Aida and Messali, Rabia and Loudjedi, Salim and Aribi, Mourad},
title = {Metformin inhibits NF-κB p65/RelA–NLRP3 inflammasome–IL-1β axis, attenuates lipid droplet accumulation, and reprograms CD14/CD16 expression in monocytes exposed to colorectal tumor-conditioned medium},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115299}
}
EUVIMED